Annexon, Inc. (ANNX)

NASDAQ: ANNX · IEX Real-Time Price · USD
3.98
+0.11 (2.84%)
Mar 29, 2023, 4:30 PM EDT - Market closed
2.84%
Market Cap 200.96M
Revenue (ttm) n/a
Net Income (ttm) -141.95M
Shares Out 50.49M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 491,785
Open 3.98
Previous Close 3.87
Day's Range 3.90 - 4.09
52-Week Range 2.06 - 7.65
Beta 0.53
Analysts Buy
Price Target 18.51 (+365.08%)
Earnings Date May 8, 2023

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with w... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 83
Stock Exchange NASDAQ
Ticker Symbol ANNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price forecast is $18.51, which is an increase of 365.08% from the latest price.

Price Target
$18.51
(365.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023

3 weeks ago - GlobeNewsWire

Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical c...

1 month ago - GlobeNewsWire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

1 month ago - GlobeNewsWire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

2 months ago - GlobeNewsWire

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications

2 months ago - GlobeNewsWire

Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

2 months ago - GlobeNewsWire

Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

3 months ago - GlobeNewsWire

Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the...

4 months ago - Zacks Investment Research

How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%

The mean of analysts' price targets for Annexon, Inc. (ANNX) points to a 246.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

4 months ago - Zacks Investment Research

Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023

Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January

5 months ago - GlobeNewsWire

Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations

8 months ago - GlobeNewsWire

Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and Eye Proceeds Support Advancement of Broad Pipeline of Novel Complement Product...

9 months ago - GlobeNewsWire

Annexon Announces $130 Million Private Placement Financing

BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

9 months ago - GlobeNewsWire

Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues

Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain.  ...

10 months ago - Benzinga

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

10 months ago - GlobeNewsWire

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings

BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

10 months ago - GlobeNewsWire

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates

11 months ago - GlobeNewsWire

Annexon Biosciences to Participate in Upcoming May Investor Conferences

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical c...

11 months ago - GlobeNewsWire

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Topline efficacy and safety data expected in first half of 2023 Topline efficacy and safety data expected in first half of 2023

1 year ago - GlobeNewsWire

Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...

1 year ago - GlobeNewsWire

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients wi...

1 year ago - GlobeNewsWire

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023

1 year ago - GlobeNewsWire

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...

1 year ago - GlobeNewsWire

Annexon Biosciences Appoints Bettina M. Cockroft, M.D.

BRISBANE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients wit...

1 year ago - GlobeNewsWire